Primary Premature Ejaculation Genetics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2020-02-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of our study is to identify the first genetic etiology of primary Premature Ejaculation (PE). We will test and evaluate the existence of genetic determinism conferring susceptibility to a life-long syndrome (primary premature ejaculation) in some patients. To this end, we plan to establish a collection of biological samples and a database of patients with this extreme syndrome, which we will analyze by Genome Wide analysis. This will lead to improvements in the biological understanding, the "knowledge" of physicians of the disease, and should improve the patients' quality of life. Not all PE cases have the same physiopathology and treatment efficiency, which depend on the specific mechanism involved in the clinical context. Our work will make it possible to develop new therapeutic approaches suitable for a large proportion of individuals presenting PE. This integrative approach combining researchers, patients and ethics committees will facilitate profound reflection, promoting the creation of suitable structures capable of receiving patients for appropriate consultations. This unique study of PE should also favor industrial partnerships.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon

NCT02202291

Primary Raynaud's Phenomenon (PR) Genetic Mutations Causing PR Study of Patients and Their Relatives (With or Without Primary PR)

COMPLETED NA

Genetic Analysis of Childhood Obesity

NCT02326480

Obesity

UNKNOWN

Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols

NCT01375543

Genetic Predisposition

COMPLETED

Pediatric Reporting of Adult-Onset Genomic Results

NCT03832985

Hereditary Breast and Ovarian Cancer Syndrome Lynch Syndrome Familial Hypercholesterolemia

COMPLETED EARLY_PHASE1

Risk of Recurrence of de Novo Mutations: Research and Quantification of Paternal Germinal Mosaicism by the Combined Use of Genomic Tools

NCT04564235

Developmental Disorders

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

2.1 Main Objective

* To identify the molecular basis of primary premature ejaculation (PPE) in humans for the development of new adapted therapy.
* Check and confirm the genetic hypothesis of PPE to fill the void of genetic knowledge about this syndrome.
* Improve knowledge of physicians on this disease to increase the comfort of life of patients.

2.2 Secondary Objectives

* Provide the basis for new therapeutic approaches.
* Expanded knowledge of the aetiology of PE and allow better management of patients.
* Develop strategies to prevent the consequences, sometimes severe , of this condition on the intimate, personal, social and professional life of these patients. Because all the PE do not have the same pathophysiology and treatment success depends on its relevance to the specific mechanism of the clinical form concerned.
* Increase the comfort of life of the patients.
* Eliminate public prejudice based on misconceptions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premature Ejaculation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Men over 18 years of age with primary Premature Ejaculation

Group Type EXPERIMENTAL

Blood sample

Intervention Type PROCEDURE

Skin biopsy

Intervention Type PROCEDURE

Questionnaire

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sample

Intervention Type PROCEDURE

Skin biopsy

Intervention Type PROCEDURE

Questionnaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. . Patients (index cases ) Prospective and retrospective cases

* Man aged over 18 years
* signing the informed consent
* Presenting primary PE
* have an affiliation to a social security system
2. . Related

* Male or female over 18 years
* be related to the index case
* signing the informed consent
* have an affiliation to a social security system

1. . Patients ( index case ) :

* Be aged under 18
* have known genetic variations that predispose or can promote psychological disorders that can lead to PE ( eg: Kallman 's Syndrome , micropenis , testicular dysgenesis , Klinfelter syndrome, Leydig cell hypoplasia )
* have had psycho- social and psycho- traumatic factors in childhood
* Inability to receive clear information on the protocol
* Person deprived of liberty by judicial or administrative decision
* Major Person subject of legal protection or unable to consent
* Refusal to be informed of an abnormality detected after genetic testing
* History of allergies to lidocaine or other anesthetic agent used during puncture or blood sample
2. . Related :

* Age \<18 years
* Inability to receive clear information about the protocol . Unable to participate in the entire study.
* No coverage by the social security system
* Absence of signature of consent or refusal of the related party
* Person deprived of liberty by judicial or administrative decision
* Major Person subject of legal protection or unable to consent
* Refusal to be informed of a genetic abnormality detected
* History of allergies to lidocaine or other anesthetic agent used during puncture or blood sample

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes